QLGN
Qualigen Therapeutics Inc
$
2.850
Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
3.120
Open
3.040
VWAP
2.99
Vol
232.08K
Mkt Cap
5.79M
Low
2.810
Amount
692.77K
EV/EBITDA(TTM)
--
Total Shares
6.31M
EV
11.87M
EV/OCF(TTM)
--
P/S(TTM)
--
Qualigen Therapeutics, Inc. is a clinical-stage therapeutics company. The Company is focused on developing treatments for adult and pediatric cancers. The Company’s business consists of one early-clinical-stage therapeutic program (QN-302) and one preclinical therapeutic program (Pan-RAS). Its lead program, QN-302, is an investigational small molecule G-quadruplexes (G4)-selective transcription inhibitor with strong binding affinity to G4s prevalent in cancer cells (such as pancreatic cancer). Its Pan-RAS program, which is at the preclinical stage, consists of a family of rat sarcoma virus (RAS) oncogene protein-protein interaction inhibitor small molecules inhibits or block mutated RAS genes’ proteins from binding to their effector proteins thereby leaving the proteins from the mutated RAS unable to cause further harm. Its QN-302 is in a Phase 1a clinical trial.
Show More
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2023Q4
0.00
-100%
-26.000
-66.45%
Estimates Revision
Stock Price
Go Up
+37.68%
In Past 3 Month
Valuation Metrics
The current forward P/E ratio for Qualigen Therapeutics Inc (QLGN.O) is -0.08, compared to its 5-year average forward P/E of -1.98. For a more detailed relative valuation and DCF analysis to assess Qualigen Therapeutics Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
N/A
5Y Average PE
-1.98
Current PE
-0.08
Overvalued PE
3.35
Undervalued PE
-7.32
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
N/A
5Y Average EV/EBITDA
0.00
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.00
Undervalued EV/EBITDA
0.00
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
N/A
5Y Average PS
3.67
Current PS
2.85
Overvalued PS
8.27
Undervalued PS
-0.94
Financials
Annual
Quarterly
FY2025Q2
N/A
Total Revenue
FY2025Q2
YoY :
-18.84%
-1.41M
Operating Profit
FY2025Q2
YoY :
+14.14%
-1.69M
Net Income after Tax
FY2025Q2
YoY :
-90.36%
-1.00
EPS - Diluted
FY2025Q2
YoY :
-25.53%
-1.10M
Free Cash Flow
FY2025Q2
N/A
Gross Profit Margin - %
FY2025Q2
N/A
Net Margin - %
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
0.0
Volume
0
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
0
0.0
Volume
Months
6-9
0
0.0
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
QLGN News & Events
Events Timeline
2025-10-28 (ET)
2025-10-28
05:29:13
Qualigen Therapeutics Announces Rebranding to AIxCrypto
2025-10-23 (ET)
2025-10-23
16:48:43
Qualigen Therapeutics Collaborates with BitGo for C10 Treasury Allocation Implementation
2025-09-30 (ET)
2025-09-30
07:19:51
Qualigen Therapeutics Secures $41M PIPE Financing with Leadership from Faraday Future
Sign Up For More Events
Sign Up For More Events
News
4.5
10-28NewsfilterQualigen Therapeutics to Change Name to AIxCrypto Following Stockholder Meeting on November 12, Outlining Three Key Objectives for 2025
2.0
10-24BenzingaIntel Shares Rise Approximately 8%; Check Out 20 Stocks Making Moves in Premarket Trading
7.5
10-24TipRanksWhat’s Behind the Surge in Qualigen Stock (QLGN) Today? Crypto Partnership Fuels the Increase
Sign Up For More News
People Also Watch
SISI
Shineco Inc
0
USD
-3.04%
SGD
Safe and Green Development Corp
1.050
USD
-0.94%
TCRT
Alaunos Therapeutics Inc
2.720
USD
+1.49%
TRNR
Interactive Strength Inc
2.470
USD
+2.70%
SNES
Senestech Inc
3.320
USD
-0.90%
MTNB
Matinas BioPharma Holdings Inc
1.380
USD
+1.47%
SCNI
Scinai Immunotherapeutics Ltd
1.400
USD
-4.11%
GNLN
Greenlane Holdings Inc
3.220
USD
+0.31%
FAQ
What is Qualigen Therapeutics Inc (QLGN) stock price today?
The current price of QLGN is 2.85 USD — it has decreased -6.56 % in the last trading day.
What is Qualigen Therapeutics Inc (QLGN)'s business?
What is the price predicton of QLGN Stock?
What is Qualigen Therapeutics Inc (QLGN)'s revenue for the last quarter?
What is Qualigen Therapeutics Inc (QLGN)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for Qualigen Therapeutics Inc (QLGN)'s fundamentals?
How many employees does Qualigen Therapeutics Inc (QLGN). have?